EP1351670A4 - Methods for treating neuropsychiatric disorders with nmda receptor antagonists - Google Patents

Methods for treating neuropsychiatric disorders with nmda receptor antagonists

Info

Publication number: EP1351670A4
Authority: EP; European Patent Office
Prior art keywords: methods; receptor antagonists; nmda receptor; neuropsychiatric disorders; treating neuropsychiatric
Prior art date: 2000-12-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

EP01990191A

Other languages

German (de)

French (fr)

Other versions

EP1351670A1 (en

Inventor

Stuart M D Lipton

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Adamas Pharmaceuticals Inc

Original Assignee

Neuromolecular Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-07

Filing date

2001-12-07

Publication date

2004-07-07

2001-12-07 Application filed by Neuromolecular Inc filed Critical Neuromolecular Inc

2001-12-07 Priority to EP07000173A priority Critical patent/EP1852113A3/en

2003-10-15 Publication of EP1351670A1 publication Critical patent/EP1351670A1/en

2004-07-07 Publication of EP1351670A4 publication Critical patent/EP1351670A4/en

Status Ceased legal-status Critical Current

Links

229940127523 NMDA Receptor Antagonists Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP01990191A 2000-12-07 2001-12-07 Methods for treating neuropsychiatric disorders with nmda receptor antagonists Ceased EP1351670A4 (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
EP07000173A EP1852113A3 (en)	2000-12-07	2001-12-07	Methods for treating neuropsychiatric disorders with NMDA receptors antagonists

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US25400700P	2000-12-07	2000-12-07
US254007P		2000-12-07
PCT/US2001/048516 WO2002045710A1 (en)	2000-12-07	2001-12-07	Methods for treating neuropsychiatric disorders with nmda receptor antagonists

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
EP07000173A Division EP1852113A3 (en)	2000-12-07	2001-12-07	Methods for treating neuropsychiatric disorders with NMDA receptors antagonists

Publications (2)

Publication Number	Publication Date
EP1351670A1 EP1351670A1 (en)	2003-10-15
EP1351670A4 true EP1351670A4 (en)	2004-07-07

Family

ID=22962564

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP01990191A Ceased EP1351670A4 (en)	2000-12-07	2001-12-07	Methods for treating neuropsychiatric disorders with nmda receptor antagonists

Country Status (8)

Country	Link
EP (1)	EP1351670A4 (en)
JP (1)	JP2004515477A (en)
CN (1)	CN1486180A (en)
AU (1)	AU2002229056A1 (en)
BR (1)	BR0116001A (en)
CA (1)	CA2436311A1 (en)
MX (1)	MXPA03005130A (en)
WO (1)	WO2002045710A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8529430B2 (en)	2002-08-01	2013-09-10	Cardiokinetix, Inc.	Therapeutic methods and devices following myocardial infarction
US10307147B2 (en)	1999-08-09	2019-06-04	Edwards Lifesciences Corporation	System for improving cardiac function by sealing a partitioning membrane within a ventricle
US7674222B2 (en)	1999-08-09	2010-03-09	Cardiokinetix, Inc.	Cardiac device and methods of use thereof
US8257428B2 (en)	1999-08-09	2012-09-04	Cardiokinetix, Inc.	System for improving cardiac function
US8388672B2 (en)	1999-08-09	2013-03-05	Cardiokinetix, Inc.	System for improving cardiac function by sealing a partitioning membrane within a ventricle
US8500795B2 (en)	1999-08-09	2013-08-06	Cardiokinetix, Inc.	Retrievable devices for improving cardiac function
US9694121B2 (en)	1999-08-09	2017-07-04	Cardiokinetix, Inc.	Systems and methods for improving cardiac function
US6444702B1 (en)	2000-02-22	2002-09-03	Neuromolecular, Inc.	Aminoadamantane derivatives as therapeutic agents
US10064696B2 (en)	2000-08-09	2018-09-04	Edwards Lifesciences Corporation	Devices and methods for delivering an endocardial device
US9332993B2 (en)	2004-08-05	2016-05-10	Cardiokinetix, Inc.	Devices and methods for delivering an endocardial device
US9332992B2 (en)	2004-08-05	2016-05-10	Cardiokinetix, Inc.	Method for making a laminar ventricular partitioning device
US9078660B2 (en)	2000-08-09	2015-07-14	Cardiokinetix, Inc.	Devices and methods for delivering an endocardial device
TW200403066A (en) *	2002-04-30	2004-03-01	Novartis Ag	New uses of substituted aminoalkanephosphonic acids
AR046314A1 (en) *	2003-11-05	2005-11-30	Merz Pharma Gmbh & Co Kgaa	COMPOSITIONS THAT INCLUDE CYCLHEXILAMINES AND AMINOADAMANTANS
UY28650A1 (en) *	2003-12-05	2005-02-28	Forest Laboratories	MEMANTINE FOR THE PREVENTION OR DECREASE OF SUICIDE CONDUCT AND FOR THE TREATMENT OF THE MAJOR DEPRESSION ASSOCIATED WITH THIS CONDUCT
TW200531680A (en) *	2004-03-03	2005-10-01	Merz Pharma Gmbh & Co Kgaa	Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
CA2569015A1 (en)	2004-06-17	2006-01-26	Forest Laboratories, Inc.	Modified release formulation of memantine
EA013474B1 (en) *	2005-06-16	2010-04-30	Форест Лэборэтериз, Инк.	Modified and immediate release memantine bead formulation
WO2007130724A2 (en)	2006-02-06	2007-11-15	Northwind Ventures	Systems and methods for volume reduction
JP5450053B2 (en) *	2006-04-13	2014-03-26	ニューロテックファーマシューティカルズカンパニーリミテッド	Pharmaceutical composition for treating or preventing cell damage and inflammatory diseases
RU2401263C2 (en) *	2008-09-10	2010-10-10	Государственное образовательное учреждение высшего профессионального образования Самарский государственный технический университет	Adamantane amino-derivatives having influenza virus inhibiting activity
IT1396556B1 (en)	2009-02-11	2012-12-14	Serra	USE OF MEMANTIN FOR THE TREATMENT OF DISTORBERS OF THE HUMOR
CN102070463A (en) *	2009-06-11	2011-05-25	辽宁利锋科技开发有限公司	Medicine memantine with adamantane structure, and derivative and analog thereof, and application to new antineoplastic indication
AU2010315535A1 (en)	2009-10-26	2012-05-03	Cardiokinetix, Inc.	Ventricular volume reduction
MX365650B (en)	2009-12-02	2019-06-10	Adamas Pharmaceuticals Inc	Amantadine compositions and methods of use.
JP5562716B2 (en)	2010-05-12	2014-07-30	花王株式会社	Voltage-gated cation channel inhibitor
US10154971B2 (en)	2013-06-17	2018-12-18	Adamas Pharma, Llc	Methods of administering amantadine
CN106687626B (en) *	2014-04-30	2021-01-26	宇凤·简·曾	Use of known compounds as D-amino acid oxidase inhibitors
CN118290279A (en) *	2014-05-29	2024-07-05	广州喜鹊医药有限公司	Salts of amantadine nitrate compounds with neuroprotective effect
RU2017114607A (en)	2014-09-28	2018-10-29	Кардиокинетикс, Инк.	DEVICES FOR THERAPY OF HEART FUNCTIONAL DISORDERS
KR20240068766A (en) *	2015-05-22	2024-05-17	비스타젠 쎄라퓨틱스, 인크.	Therapeutic uses of l-4-chlorokynurenine
DE102018107407A1 (en)	2017-03-28	2018-10-04	Edwards Lifesciences Corporation	POSITIONING, INSERTING AND RETRIEVING IMPLANTABLE DEVICES
ES3015758T3 (en) *	2017-08-01	2025-05-07	Stuart A Lipton	Nitrosynapsin for use in treating autism spectrum disorder
AU2018372938B2 (en) *	2017-11-22	2025-04-10	Panorama Research, Inc.	Aminoadamantyl nitrate compounds and their use to treat CNS disorders
CN109206317B (en) *	2018-09-12	2021-07-09	青岛海蓝医药有限公司	A kind of preparation technology of amantadine nitrate derivatives
CN110938006A (en) *	2019-12-04	2020-03-31	重庆植恩药业有限公司	Preparation method of memantine hydrochloride impurity C
CN114544826B (en) *	2020-11-24	2023-12-08	重庆医科大学	Use of reagents for detecting histidine in plasma in preparing depression detection kits

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994005275A1 (en) *	1992-09-03	1994-03-17	The Children's Medical Center Corporation	Method of preventing nmda receptor-mediated neuronal damage
WO1994006428A1 (en) *	1992-09-22	1994-03-31	The Children's Medical Center Corporation	Method of preventing nmda receptor complex-mediated neuronal damage
WO2001062706A1 (en) *	2000-02-22	2001-08-30	Panorama Research, Inc.	Aminoadamantane derivatives as therapeutic agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS584718A (en) *	1981-06-30	1983-01-11	Nippon Chibagaigii Kk	Medicinal pharmaceutical used for novel indication

2001
- 2001-12-07 BR BR0116001-0A patent/BR0116001A/en not_active Application Discontinuation
- 2001-12-07 EP EP01990191A patent/EP1351670A4/en not_active Ceased
- 2001-12-07 CA CA002436311A patent/CA2436311A1/en not_active Abandoned
- 2001-12-07 AU AU2002229056A patent/AU2002229056A1/en not_active Abandoned
- 2001-12-07 WO PCT/US2001/048516 patent/WO2002045710A1/en not_active Ceased
- 2001-12-07 JP JP2002547494A patent/JP2004515477A/en active Pending
- 2001-12-07 MX MXPA03005130A patent/MXPA03005130A/en unknown
- 2001-12-07 CN CNA018217958A patent/CN1486180A/en active Pending

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994005275A1 (en) *	1992-09-03	1994-03-17	The Children's Medical Center Corporation	Method of preventing nmda receptor-mediated neuronal damage
WO1994006428A1 (en) *	1992-09-22	1994-03-31	The Children's Medical Center Corporation	Method of preventing nmda receptor complex-mediated neuronal damage
WO2001062706A1 (en) *	2000-02-22	2001-08-30	Panorama Research, Inc.	Aminoadamantane derivatives as therapeutic agents

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PARSONS C G ET AL: "Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - A review of preclinical data", NEUROPHARMACOLOGY, vol. 38, no. 6, June 1999 (1999-06-01), pages 735 - 767, XP002279262, ISSN: 0028-3908 *
See also references of WO0245710A1 *
YAMADA KAZUO ET AL: "Changes in symptoms and plasma homovanillic acid with amantadine hydrochloride in chronic schizophrenia", BIOLOGICAL PSYCHIATRY, vol. 41, no. 10, 1997, pages 1062 - 1064, XP002279263, ISSN: 0006-3223 *

Also Published As

Publication number	Publication date
WO2002045710A1 (en)	2002-06-13
EP1351670A1 (en)	2003-10-15
JP2004515477A (en)	2004-05-27
MXPA03005130A (en)	2004-12-06
BR0116001A (en)	2004-07-06
AU2002229056A1 (en)	2002-06-18
WO2002045710A9 (en)	2003-04-24
CN1486180A (en)	2004-03-31
CA2436311A1 (en)	2002-06-13

Legal Events

Date	Code	Title	Description
2003-08-29	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2003-10-15	17P	Request for examination filed	Effective date: 20030707
2003-10-15	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
2003-10-15	AX	Request for extension of the european patent	Extension state: AL LT LV MK RO SI
2004-07-07	A4	Supplementary search report drawn up and despatched	Effective date: 20040526
2005-06-01	17Q	First examination report despatched	Effective date: 20050415
2006-08-09	RIN1	Information on inventor provided before grant (corrected)	Inventor name: WENT, GREGORY T. Inventor name: LIPTON, STUART, M.D.
2006-08-23	RIN1	Information on inventor provided before grant (corrected)	Inventor name: WENT, GREGORY T. Inventor name: LIPTON, STUART, M.D.
2007-04-12	APBN	Date of receipt of notice of appeal recorded	Free format text: ORIGINAL CODE: EPIDOSNNOA2E
2007-05-23	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: NEUROMOLECULAR INC.
2007-06-14	APBR	Date of receipt of statement of grounds of appeal recorded	Free format text: ORIGINAL CODE: EPIDOSNNOA3E
2007-07-06	APAZ	Date of receipt of statement of grounds of appeal deleted	Free format text: ORIGINAL CODE: EPIDOSDNOA3E
2007-07-10	APBR	Date of receipt of statement of grounds of appeal recorded	Free format text: ORIGINAL CODE: EPIDOSNNOA3E
2007-08-09	APAF	Appeal reference modified	Free format text: ORIGINAL CODE: EPIDOSCREFNE
2010-08-13	APBT	Appeal procedure closed	Free format text: ORIGINAL CODE: EPIDOSNNOA9E
2010-08-20	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED
2010-09-22	18R	Application refused	Effective date: 20100806

Publication	Publication Date	Title
EP1351670A4 (en)	2004-07-07	Methods for treating neuropsychiatric disorders with nmda receptor antagonists
PL365377A1 (en)	2005-01-10	Amide derivatives as nmda receptor antagonists
HUP0301671A3 (en)	2010-03-29	4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists, process for their preparation and their use
IL152775A0 (en)	2003-06-24	Il-8 receptor antagonists
IL152700A0 (en)	2003-06-24	Substituted 1-aminoalkyl-lactams and their use as muscarinc receptor antagonists
PL353854A1 (en)	2003-12-01	Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain
IL157770A0 (en)	2004-03-28	Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
PL358584A1 (en)	2004-08-09	Cyclohexylamine derivative as subtype selective nmda receptor antagonists
PL356990A1 (en)	2004-07-12	Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists
DZ3309A1 (en)	2001-09-07	Il-8 receptor antagonists
PL352232A1 (en)	2003-08-11	Il-8 receptor antagonists
IL161801A0 (en)	2005-11-20	Unsaturated amino-alkylcyclohexane nmda, 5ht3 and neuronal nicotinic receptor antagonists
EP1296958A4 (en)	2004-01-28	Iminopyrimidine nmda nr2b receptor antagonists
IL151431A0 (en)	2003-04-10	Il-8 receptor antagonists
ZA200104187B (en)	2002-11-22	1-Amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists.
AU2002360819A8 (en)	2003-07-24	Cyclohexano- and cycloheptapyrazole derivative compounds, for use in diseases associated with the 5-ht2c receptor
IL144299A0 (en)	2002-05-23	N-triazolymethyl-piperazine derivatives as neurokinin receptor antagonists
EP1274415A4 (en)	2005-09-07	Il-8 receptor antagonists
AP2002002599A0 (en)	2002-09-30	Il-8 receptor antagonists
IL146046A0 (en)	2002-07-25	Il-8 receptor antagonists
EP1265905A4 (en)	2003-03-12	Il-8 receptor antagonists
MXPA03003892A (en)	2003-07-28	Bombesin receptor antagonists.
EP1351687A4 (en)	2004-01-21	Urotensin-ii receptor antagonists
EP1274413A4 (en)	2005-08-10	Il-8 receptor antagonists
EP1263427A4 (en)	2005-08-24	Il-8 receptor antagonists